Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database

BACKGROUND: For decades, peginterferon and ribavirin (PegIFN/RBV) have been the standard-of-care for chronic hepatitis C virus (CHC) infection. However, the actual cost-effectiveness of this therapy remains unclear. We purposed to explore the real-world cost effectiveness for subgroups of treatment-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Pei-Chien, Liu, Ta-Wei, Tsai, Yi-Shan, Ko, Yu-Min, Chen, Kuan-Yu, Lin, Ching-Chih, Huang, Ching-I, Liang, Po-Cheng, Lin, Yi-Hung, Hsieh, Ming-Yen, Hou, Nai-Jen, Huang, Chung-Feng, Yeh, Ming-Lun, Lin, Zu-Yau, Chen, Shinn-Cherng, Dai, Chia-Yen, Chuang, Wan-Long, Huang, Jee-Fu, Yu, Ming-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459714/
https://www.ncbi.nlm.nih.gov/pubmed/28562549
http://dx.doi.org/10.1097/MD.0000000000006984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459714/
https://www.ncbi.nlm.nih.gov/pubmed/28562549
http://dx.doi.org/10.1097/MD.0000000000006984

Ejemplares similares